General MedicationsORALGeneric

PONATINIB HYDROCHLORIDE

Standard Dose

EQ 15MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: UNKNOWN Marketing status: Discontinued

Summary

Approval overview PONATINIB HYDROCHLORIDE is listed in Drugs@FDA under application 215893 (ANDA).

Review priority: UNKNOWN Marketing status: Discontinued Active ingredient PONATINIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 15MG BASE Sponsor APOTEX Submission history Latest submission status date: 2024-11-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview PONATINIB HYDROCHLORIDE is listed in Drugs@FDA under application 215893 (ANDA). Review priority: UNKNOWN Marketing status: Discontinued Active ingredient PONATINIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 15MG BASE Sponsor APOTEX Submission history Latest submission status date: 2024-11-27 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: UNKNOWN

Interaction Notes

No interaction notes stored yet.